Erlotinib in Combination With Cisplatin as Radiosensitizing Agents in Women Receiving Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Cervix; A Phase I Trial.

Trial Profile

Erlotinib in Combination With Cisplatin as Radiosensitizing Agents in Women Receiving Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Cervix; A Phase I Trial.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Cisplatin; Erlotinib
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 15 May 2008 Status change from in progress to discontiuned, as reported on clinicaltrials.gov
    • 06 Feb 2008 Status changed from recruiting to in progress.
    • 11 Apr 2007 Status changed from initiated to recruiting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top